{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:38:17Z","timestamp":1792175897403,"version":"4.4.0"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is characterized by molecular, immunological, and clinical heterogeneity and this has been reflected with changing paradigms in the treatment landscape of AML in recent years. Despite high remission rates with conventional chemotherapy regimens, most patients eventually relapse and have disappointing outcomes in the relapsed setting, with estimated 5-year overall survival rates ranging from 10-15%. Immune checkpoint inhibitors (ICIs) restrain T-cell suppressive signals delivered through cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1)\/programmed death-ligand 1 (PD-L1) pathways and promote antitumor immune responses and these agents have been explored successfully in the treatment of many malignancies. Although ICIs have demonstrated long-term clinical benefit in solid tumors such as melanoma or lung cancer, AML has historically been considered an immunologically \u201ccold\u201d tumor and responses have been less robust. Furthermore, the impact of T-cell functional states and the tumor microenvironment in response to standard chemotherapy regimens, molecularly targeted therapies, and immunotherapies is poorly understood. Recent advances in multimodal omics technologies have deepened our understanding of the dynamic cellular interactions at the AML immune interface and immune gene expression profiling can potentially be integrated with clinically validated molecular prognosticators to further stratify AML into potential tumor microenvironment subgroups that could more aptly respond to ICIICIs to reinvigorate dysfunctional T cells and modulate cytotoxicity. This review will attempt to summarize recent discoveries on T-cell functional states in AML and their impact on response to ICIICIs as well as acquired mechanisms of resistance to ICIICIs. Furthermore, strategies to potentially overcome resistance to ICIICIs in the immune-based treatment of AML will be highlighted to provide an outlook for future strategies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1608433","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:16Z","timestamp":1771910356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Overcoming resistance to immune checkpoint inhibitor therapy in acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Vaibhav","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.333","article-title":"Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)","volume":"23","author":"Kotsianidis","year":"2009","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.critrevonc.2016.04.020","article-title":"Harnessing the immune system in acute myeloid leukaemia","volume":"103","author":"Austin","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00184","article-title":"A T cell view of the bone marrow","volume":"7","author":"Bonomo","year":"2016","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1265299","article-title":"Progress of research on PD-1\/PD-L1 in leukemia","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"B7","article-title":"Prognostic relevance of serum beta 2-microglobulin in acute myeloid leukemia","volume":"6","author":"Melillo","year":"1992","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","article-title":"Immunogenomic landscape of hematological Malignancies","volume":"38","author":"Dufva","year":"2020","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618710","article-title":"One stone, two birds: the roles of Tim-3 in acute myeloid leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02566-x","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"39","author":"Reinhardt","year":"2025","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9081051","article-title":"The ups and downs of STAT inhibition in acute myeloid leukemia","volume":"9","author":"Moser","year":"2021","journal-title":"Biomedicines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the NKG2D\/NKG2D-L axis in acute myeloid leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414167112","article-title":"beta-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10","volume":"112","author":"Fu","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B17","article-title":"GSK-3beta in dendritic cells exerts opposite functions in regulating cross-priming and memory CD8 T cell responses independent of beta-catenin","volume":"12","author":"Fu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","author":"Chang","year":""},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFNgamma signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2016.0023","article-title":"Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang","volume":"13","author":"Zhou","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15932","article-title":"Single-cell RNA-seq reveals a microenvironment and an exhaustion state of T\/NK cells in acute myeloid leukemia","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw4871","article-title":"Single-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML","volume":"11","author":"Gui","year":"2025","journal-title":"Sci Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6040110","article-title":"Dissecting the immune landscape of acute myeloid leukemia","volume":"6","author":"Davidson-Moncada","year":"2018","journal-title":"Biomedicines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.coph.2025.102526","article-title":"Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction","volume":"82","author":"Wang","year":"2025","journal-title":"Curr Opin Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","article-title":"STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112823","article-title":"High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations","volume":"20","author":"Brodska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj5104","article-title":"Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function","volume":"377","author":"Notarangelo","year":"2022","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0506","article-title":"Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/leu.2016.207","article-title":"RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features","volume":"30","author":"Gaidzik","year":"2016","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06418-7","article-title":"The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia","volume":"104","author":"Sun","year":"2025","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205584","article-title":"Clonal hematopoiesis is associated with changes to T cell contexture in solid tumours","volume":"144","author":"Rajwani","year":"2024","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/path.5907","article-title":"\u2018Know thyself\u2019 - host factors influencing cancer response to immune checkpoint inhibitors","volume":"257","author":"Gunjur","year":"2022","journal-title":"J Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.1038\/s41598-022-19972-1","article-title":"Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia","volume":"12","author":"Marconato","year":"2022","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/14653240500499507","article-title":"CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system","volume":"8","author":"Zhong","year":"2006","journal-title":"Cytotherapy"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of Malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.05.11","article-title":"Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia","volume":"29","author":"Tan","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020236","article-title":"Targeting immune signaling checkpoints in acute myeloid leukemia","volume":"8","author":"Giannopoulos","year":"2019","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bjh.15078","article-title":"Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword","volume":"181","author":"Hobo","year":"2018","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2017.1383542","article-title":"Checkpoint inhibition in pediatric hematologic Malignancies","volume":"34","author":"Davis","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41408-021-00453-z","article-title":"Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study","volume":"11","author":"Reville","year":"2021","journal-title":"Blood Cancer J"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015176","article-title":"Randomized phase II study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia","author":"Pyzer","year":"2025","journal-title":"Blood Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165894","article-title":"Promising safety and efficacy results from an ongoing phase 1b study of pembrolizumab combined with decitabine in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML)","volume":"140","author":"Agrawal","year":"2022","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531","article-title":"Immune checkpoint inhibitors in acute myeloid leukemia: A meta-analysis","volume":"12","author":"Gomez-Llobell","year":"2022","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22141","article-title":"High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1182\/blood-2019-126065","article-title":"Final clinical results of a phase II study of high dose cytarabine followed by pembrolizumab in relapsed\/refractory AML","volume":"134","author":"Zeidner","year":"2019","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1182\/blood-2019-122896","article-title":"Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and pts with higher-risk myelodysplastic syndromes (HR-MDS): results from a large, international, randomized phase 2 study","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400557","article-title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion","volume":"193","author":"Ferris","year":"2014","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476904","article-title":"CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1087434","article-title":"T cell exhaustion assessment algorism in tumor microenvironment predicted clinical outcomes and immunotherapy effects in glioma","volume":"13","author":"Chen","year":"2022","journal-title":"Front Genet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B68","article-title":"Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification","author":"Li","year":""},{"key":"B69","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","article-title":"Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML","volume":"8","author":"Tan","year":"2020","journal-title":"biomark Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11063","article-title":"Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1","volume":"7","author":"Darwish","year":"2016","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30728-X","article-title":"AML-190: anti-TIM-3 antibody MBG453 in combination with hypomethylating agents (HMAs) in patients with high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia: A phase 1 study","volume":"20","author":"Brunner","year":"2020","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1865814","article-title":"TIM-3 pathway dysregulation and targeting in cancer","volume":"21","author":"Zeidan","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401025","article-title":"Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling","volume":"193","author":"Bae","year":"2014","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0436","article-title":"PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer","volume":"21","author":"Qiu","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283648","article-title":"FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"116","author":"Whitman","year":"2010","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1744-y","article-title":"Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia","volume":"92","author":"Rickmann","year":"2013","journal-title":"Ann Hematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1231-2","article-title":"Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication","volume":"90","author":"Rickmann","year":"2011","journal-title":"Ann Hematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13236","article-title":"Higher frequency of the CTLA-4(+) LAG-3(+) T-cell subset in patients with newly diagnosed acute myeloid leukemia","volume":"16","author":"Chen","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"Chen","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol Rev"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 axis regulates human T cell function","volume":"188","author":"Lozano","year":"2012","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13324","article-title":"CD155, an onco-immunologic molecule in human tumors","volume":"108","author":"Gao","year":"2017","journal-title":"Cancer Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2626","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients","volume":"22","author":"Kong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02978-5","article-title":"Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis","volume":"71","author":"Liu","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci Trans Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106550108","article-title":"CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction","volume":"108","author":"Zhao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3585","article-title":"Type 3 repeat\/C-terminal domain of thrombospondin-1 triggers caspase-independent cell death through CD47\/alphavbeta3 in promyelocytic leukemia NB4 cells","volume":"106","author":"Saumet","year":"2005","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"B94","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results","volume":"40","author":"Daver","year":"","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157606","article-title":"Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine and venetoclax in patients with acute myeloid leukemia (ASPEN-05): results from phase 1a dose escalation part","volume":"140","author":"Garcia-Manero","year":"2022","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134391","article-title":"A phase I\/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","author":"Andr\u00e9","year":""},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546717","article-title":"Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors","volume":"16","author":"Alsaafeen","year":"2025","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088886","article-title":"The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment","volume":"13","author":"Shi","year":"2022","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12228","article-title":"Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment","volume":"92","author":"Kronig","year":"2014","journal-title":"Eur J Haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1485546","article-title":"Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0188-5","article-title":"STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer","volume":"119","author":"Ghaffari","year":"2018","journal-title":"Br J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-023-01452-3","article-title":"Beyond DNA sensing: expanding the role of cGAS\/STING in immunity and diseases","volume":"46","author":"Seok","year":"2023","journal-title":"Arch Pharm Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175033","article-title":"STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma","volume":"134","author":"Najem","year":"2024","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ccell.2025.02.014","article-title":"Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy","volume":"43","author":"Song","year":"2025","journal-title":"Cancer Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1937123","article-title":"Reversing T-cell exhaustion in immunotherapy: a review on current approaches and limitations","volume":"25","author":"Tabana","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120775","article-title":"Emerging strategies for combination checkpoint modulators in cancer immunotherapy","volume":"128","author":"Popovic","year":"2018","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143733","article-title":"Cellular therapy for lung cancer: focusing on chimeric antigen receptor T (CAR T) cells and tumor-infiltrating lymphocyte (TIL) therapy","volume":"15","author":"Katiyar","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328193","article-title":"Mechanisms underlying immunosuppression by regulatory cells","volume":"15","author":"Goldmann","year":"2024","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping polarization of tumor-associated macrophages in cancer immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2012.680634","article-title":"Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives","volume":"41","author":"Raber","year":"2012","journal-title":"Immunol Invest"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00783","article-title":"Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment","author":"Haist","year":""},{"key":"B120","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061104","article-title":"Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function","volume":"203","author":"Serafini","year":"2006","journal-title":"J Exp Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387975","article-title":"Regulation of Treg cells by cytokine signaling and co-stimulatory molecules","volume":"15","author":"Zong","year":"2024","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","article-title":"Treg and CTLA-4: two intertwining pathways to immune tolerance","volume":"45","author":"Walker","year":"2013","journal-title":"J Autoimmun"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1325946","article-title":"Targeting tumor-infiltrating tregs for improved antitumor responses","volume":"15","author":"Qin","year":"2024","journal-title":"Front Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1141208","article-title":"The role of interleukin-15 in the development and treatment of hematological Malignancies","volume":"14","author":"Sindaco","year":"2023","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J Clin Invest"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102700","article-title":"A complex metabolic network confers immunosuppressive functions to myeloid-derived suppressor cells (MDSCs) within the tumour microenvironment","volume":"10","author":"Hofer","year":"2021","journal-title":"Cells"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12944","article-title":"Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes","volume":"7","author":"Matre","year":"2016","journal-title":"Oncotarget"},{"key":"B131","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-019-0664-6","article-title":"The therapeutic potential of targeting tryptophan catabolism in cancer","volume":"122","author":"Opitz","year":"2020","journal-title":"Br J Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ccell.2019.06.003","article-title":"Mubritinib targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia","volume":"36","author":"Baccelli","year":"2019","journal-title":"Cancer Cell"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abp9586","article-title":"Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies","volume":"16","author":"Germon","year":"2023","journal-title":"Sci Signal"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"Luksza","year":"2017","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","article-title":"Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers","volume":"25","author":"Pirouzbakht","year":"2025","journal-title":"Clin Exp Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"NPJ Digit Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/life15020283","article-title":"Towards the prediction of responses to cancer immunotherapy: A multi-omics review","volume":"15","author":"Tao","year":"2025","journal-title":"Life (Basel)"},{"key":"B138","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41525-025-00465-9","article-title":"PD-1 transcriptomic landscape across cancers and implications for immune checkpoint blockade outcome","volume":"10","author":"Chen","year":"2025","journal-title":"NPJ Genom Med"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci Transl Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s43018-023-00518-x","article-title":"Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-023-00518-x","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood.2024024000","article-title":"IL-9 secreted by leukemia stem cells induces Th1-skewed CD4+ T cells, which promote their expansion","volume":"144","author":"Radpour","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1608433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:19Z","timestamp":1771910359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1608433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":142,"alternative-id":["10.3389\/fonc.2026.1608433"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1608433","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"article-number":"1608433"}}